Prognostic and Predictive Value of Tertiary Lymphoid Structures in Turbt Materials: Should It Be Seated in the Routine Pathological Examination, and Can It Be Used in Deciding on the Treatment Method?

dc.contributor.author Yilmaz, Fatih
dc.contributor.author Sagir, Suleyman
dc.contributor.other Department of Surgical Medical Sciences / Cerrahi Tıp Bilimleri Bölümü
dc.contributor.other 10. Faculty of Medicine / Tıp Fakültesi
dc.contributor.other 01. Mardin Artuklu University / Mardin Artuklu Üniversitesi
dc.date.accessioned 2025-02-15T19:35:58Z
dc.date.available 2025-02-15T19:35:58Z
dc.date.issued 2024
dc.description SAGIR, SULEYMAN/0000-0001-5300-8071 en_US
dc.description.abstract Objective: This study aims to reveal the importance of tertiary lymphoid structures (TLS) in transurethral resection of bladder tumor (TURBT) materials with a practical and applicable method in which the effect of a certain threshold value on survival and treatment response can be implicated. Methods: TURBT materials that had not previously received any treatment (chemotherapy, radiotherapy, or immunotherapy) and were diagnosed for the first time at Mardin Training and Research Hospital between 2014 and 2022 were included in the study. The maximum TLS per 4x magnification field (field diameter: 4.5 mm) was recorded. Grouping and statistical analysis of the TLS number were performed using threshold values of ">= 1", ">= 2", and ">= 3". Results: TLSs were more frequently found in high-grade tumors (P = 0.008) and showed a strong association with stage progression (P < 0.001). It was also significantly associated with many adverse histopathological parameters. Conversely, high TLS (>= 1, >= 2, and >= 3) appeared to be associated with fewer recurrences (P = 0.032, P = 0.001, and P = 0.018, respectively), and cases with higher TLS showed longer recurrence-free survival (P = 0.089, P = 0.023, P = 0.037, respectively). TLS >= 3 was found to be an independent parameter that was associated with favorable RFS (P = 0.019, HR = 0.401), and multifocality was found to be an independent risk factor for RFS (P = 0.023, HR = 2.302). Conclusion: This study is the first to demonstrate the relationship between the presence and specific thresholds of TLS in TURBT materials with prognostic parameters. Including this information in the routine pathological examination of TURBT materials will allow a more accurate approach to treatment and follow-up, especially in patients with non-muscle invasive bladder cancer (NMIBC). en_US
dc.identifier.citationcount 0
dc.identifier.doi 10.1016/j.urolonc.2024.06.010
dc.identifier.issn 1078-1439
dc.identifier.issn 1873-2496
dc.identifier.scopus 2-s2.0-85200354776
dc.identifier.uri https://doi.org/10.1016/j.urolonc.2024.06.010
dc.identifier.uri https://hdl.handle.net/20.500.12514/6074
dc.language.iso en en_US
dc.publisher Elsevier Science inc en_US
dc.rights info:eu-repo/semantics/openAccess en_US
dc.subject Turbt en_US
dc.subject Tertiary Lymphoid Structure en_US
dc.subject Bladder Cancer en_US
dc.subject Prognosis en_US
dc.subject Recurrence en_US
dc.subject Https en_US
dc.title Prognostic and Predictive Value of Tertiary Lymphoid Structures in Turbt Materials: Should It Be Seated in the Routine Pathological Examination, and Can It Be Used in Deciding on the Treatment Method? en_US
dc.type Article en_US
dspace.entity.type Publication
gdc.author.id SAGIR, SULEYMAN/0000-0001-5300-8071
gdc.author.institutional Sağır, Süleyman
gdc.author.scopusid 57958818900
gdc.author.scopusid 57222670818
gdc.author.wosid Sagir, Suleyman/IAM-8192-2023
gdc.coar.access open access
gdc.coar.type text::journal::journal article
gdc.description.department Artuklu University en_US
gdc.description.departmenttemp [Yilmaz, Fatih] Mardin Training & Res Hosp, Pathol Lab, Mardin, Turkiye; [Sagir, Suleyman] Mardin Artuklu Univ, Dept Urol, Mardin, Turkiye en_US
gdc.description.endpage 4.50E+24 en_US
gdc.description.issue 12 en_US
gdc.description.publicationcategory Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı en_US
gdc.description.scopusquality Q2
gdc.description.startpage 4.50E+15 en_US
gdc.description.volume 42 en_US
gdc.description.woscitationindex Science Citation Index Expanded
gdc.identifier.pmid 39089974
gdc.identifier.wos WOS:001361028200001
gdc.openalex.fwci 0.796
gdc.scopus.citedcount 1
gdc.wos.citedcount 1
relation.isAuthorOfPublication c9134177-e6b4-49f5-b988-bffb4e620b29
relation.isAuthorOfPublication.latestForDiscovery c9134177-e6b4-49f5-b988-bffb4e620b29
relation.isOrgUnitOfPublication 699b05f8-13b6-432a-a67f-7cf80b49367a
relation.isOrgUnitOfPublication 3f27f943-1869-4252-af6a-9ec8b114c727
relation.isOrgUnitOfPublication 39ccb12e-5b2b-4b51-b989-14849cf90cae
relation.isOrgUnitOfPublication.latestForDiscovery 699b05f8-13b6-432a-a67f-7cf80b49367a

Files